Did peptides 'ruin his life'? What bodybuilding culture gets wrong

What did @ehhkung actually say?

The video tells a cautionary story about a 23-year-old named Jake who allegedly developed insulin-dependent diabetes after using growth hormone peptides for bodybuilding. The creator says these peptides "destroy your pancreas" and make the body "stop responding to insulin. Forever." The framing is urgent: Jake now "injects insulin every single day just to stay alive," and "hundreds of 20-somethings" are supposedly facing the same outcome. The core claim is that growth hormone-releasing peptides caused permanent, irreversible diabetes in a young, otherwise healthy person, and that this is an undisclosed widespread risk.

The video does not name which specific peptides Jake used. It also does not cite any studies, case reports, or clinical data. It presents a single anecdote as evidence of a mass public health crisis. That framing matters when we evaluate whether the science actually supports the story.

Does the science back this up?

Partially, but not in the way the video presents it. Growth hormone secretagogues, including peptides like CJC-1295, ipamorelin, and MK-677, do have documented effects on glucose metabolism, and that part is real. The permanent, pancreas-destroying claim is not well supported.

MK-677 (ibutamoren), which is technically not a peptide but a ghrelin mimetic, has been shown in clinical trials to transiently increase fasting blood glucose and insulin resistance. A study by Nass et al. (2008, Annals of Internal Medicine) found that MK-677 significantly increased fasting glucose in older adults, enough that the trial was modified. GHRH analogues like CJC-1295 also elevate GH and IGF-1, which can reduce insulin sensitivity through well-understood counter-regulatory mechanisms. None of this is hidden, but none of the peer-reviewed literature describes permanent pancreatic destruction in otherwise healthy young adults as a documented outcome.

Type 1 diabetes from peptide use is not an established clinical pattern. Type 2 insulin resistance after prolonged GH elevation is a known risk, but it is generally considered reversible upon discontinuation in metabolically healthy individuals, not a life sentence.

What did they get wrong (or right)?

The video gets the general direction of the risk right but catastrophizes it into something the evidence does not support. Saying these peptides "destroy your pancreas" is inaccurate. The pancreas is not the primary site of GH-driven glucose dysregulation. GH excess primarily causes peripheral insulin resistance in muscle and fat tissue, not pancreatic beta-cell destruction, which is the mechanism behind Type 1 diabetes. These are fundamentally different disease processes.

The claim that the effect is "forever" is also not supported. While chronic supraphysiologic GH exposure, as seen in acromegaly, can eventually impair beta-cell function over years, that is not the same as a 23-year-old using peptide stacks for a few months. A review by Møller and Jørgensen (2009, Endocrine Reviews) notes that GH-induced insulin resistance is largely reversible when GH levels normalize.

Where the video deserves partial credit: these compounds do carry real metabolic risks that are frequently downplayed in bodybuilding communities. The "no side effects" framing common in online peptide promotion is legitimately irresponsible, and calling that out is fair. The problem is the video replaces one form of misinformation with another.

What should you actually know?

Growth hormone peptides and secretagogues are not side-effect-free. Anyone telling you otherwise is either uninformed or selling something. The metabolic risks are real, documented, and worth taking seriously, especially for young people whose long-term health outcomes matter more than short-term physique changes.

That said, the specific mechanism described in this video is wrong in clinically important ways. Permanent insulin-dependent diabetes caused by a short peptide cycle is not a documented pattern in the peer-reviewed literature. If Jake's story is real, there may be other explanations: pre-existing autoimmune susceptibility, use of exogenous HGH rather than secretagogues, contaminated compounds, or concurrent drug use. None of those possibilities are explored.

The broader issue is that many of these peptides are not FDA-approved for the uses promoted online. They are often sourced from unregulated suppliers, which introduces real risks around purity, dosing accuracy, and contamination. The risk is real. It just is not the risk the video describes.

• MK-677 has shown clinically significant glucose elevation in human trials (Nass et al., 2008).
• GH-induced insulin resistance is primarily peripheral, not pancreatic destruction.
• Reversibility upon discontinuation is the expected outcome in otherwise healthy individuals.
• Unregulated peptide sourcing introduces contamination risks that are separate from the pharmacological risks.
• Anyone experiencing glucose dysregulation on any GH-related compound should stop use and consult an endocrinologist.